Abeona Therapeutics: Analyst Forecast Sparks Investor Optimism

Abeona Therapeutics shares concluded the latest trading session at $5.07, with market attention focused squarely on a significant forecast revision from Cantor Fitzgerald that substantially raises expectations for 2025 performance.

Quarterly Performance Exceeds Expectations

The biopharmaceutical company delivered a stronger-than-anticipated third quarter 2025 performance, reporting a loss per share of just $0.10. This figure surpassed analyst consensus estimates of a $0.27 loss by $0.17 per share. Despite this improved bottom-line performance, the company’s revenue for the trailing twelve months remains modest at $400,000.

Major Analyst Firm Boosts Projections

Cantor Fitzgerald has significantly upgraded its earnings outlook for Abeona’s 2025 fiscal year. Research analyst K. Kluska raised the earnings per share (EPS) forecast from $1.15 to $1.33, positioning the new estimate well above the market consensus of $1.16. The firm maintains its “Moderate Buy” rating on the stock with a $20.00 price target, suggesting nearly 300% upside potential from current trading levels. Looking further ahead, projections for 2026 anticipate a loss of $0.36 per share.

Should investors sell immediately? Or is it worth buying Abeona Therapeut.?

Ownership Structure and Market Positioning

An examination of the company’s ownership distribution reveals:

• Institutional investors hold a dominant 80.6% stake
• Company insiders divested 78,612 shares over the previous three months
• Market capitalization stands at $274.75 million
• The stock has traded between $3.93 and $7.54

With a price-to-earnings ratio of 4.59, Abeona continues to present an attractive valuation profile. The next critical test arrives on March 18, 2026, when subsequent quarterly results will indicate whether the elevated expectations for 2025 remain justified.